

in ATIII involved in the prediction of 24-item Hamilton Depression Rating Scale in the follow-up study with significant predictive values ( $p=0.0240$  and  $0.0233$ , respectively).

**Conclusions:** This study detected a reduction in ATIII after occipital rTMS, further revealed the relationships between change in ATIII and therapeutic response, and ultimately provided evidence for the potential of ATIII as a biomarker for the evaluation and prediction of antidepressive effect.

**Disclosure:** No significant relationships.

**Keywords:** major depressive disorder; antithrombin III; occipital repetitive transcranial magnetic stimulation antidepressive effect; biomarker

## O106

### Use of pharmacotherapies for treatment resistant depression in finland: A nationwide cohort study

H. Taipale<sup>1\*</sup>, M. Lähteenvuo<sup>1</sup>, A. Tanskanen<sup>2</sup>, S. Rannanpää<sup>3</sup> and J. Tiihonen<sup>2</sup>

<sup>1</sup>Forensic Psychiatry, Niuvanniemi Hospital, Kuopio, Finland;

<sup>2</sup>Department Of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden and <sup>3</sup>Janssen-cilag, Janssen-Cilag, Espoo, Finland

\*Corresponding author.

doi: 10.1192/j.eurpsy.2021.311

**Introduction:** There is a lack of knowledge on utilized pharmacotherapies for treatment resistant depression (TRD).

**Objectives:** To investigate the courses of treatment of TRD.

**Methods:** All patients aged 16-65 years and diagnosed with depression in Finland during 2004-2016 were included (identified from nationwide registers for inpatient and specialized outpatient care, sick leaves and disability pensions). New antidepressant users were identified with six-month washout period and followed up for two years to observe the possible emergence of TRD, which was defined as initiation of a third treatment after having two failed pharmacological treatments with adequate duration. Pharmacological treatments were analyzed using PRE2DUP-method.

**Results:** During follow-up, 177,144 persons had their first registered depression (mean age:39.5, 62.5% women). Of them, 10.9% (N=19,322) met TRD criteria. Among the TRD patients, most common first and second lines antidepressants were as follows: SSRIs (44.6%), mirtazapine (19.0%) and SNRIs (16.5%). As the third line of treatment, 44.2% of TRD patients had antidepressant monotherapy, 32.1% a combination of  $\geq 2$  antidepressants, 15.8% antipsychotic or mood stabilizer augmentation and an antidepressant, 4.9% both combination of antidepressants and an augmentation with a mood stabilizer or antipsychotic, 2.7% antipsychotic or mood stabilizer monotherapy and 0.3% ECT monotherapy. Of TRD patients, 36.2% (N=6985) progressed to the fourth line of treatment and most common treatments were antidepressant monotherapy (37.5%), antidepressant combinations (30.8%) and augmentation (20.3%).

**Conclusions:** Although antidepressant combination and augmentation strategies became more frequent, antidepressant monotherapies were still the most common third and fourth lines of depression treatment.

**Disclosure:** The study was funded by Janssen and SR is an employee of Janssen.

**Keywords:** Treatment Resistant Depression; pharmacotherapy

## O108

### Identification of risk-factors for the development of depressive symptoms in perinatal period: A longitudinal study

A. Vece<sup>1\*</sup>, G. Tarantino<sup>1</sup>, M. Carfagno<sup>1</sup>, M. Raia<sup>1</sup>, C. Ciampi<sup>1</sup>, M. Di Vincenzo<sup>1</sup>, A. Pitocco<sup>1</sup>, G. Sampogna<sup>1</sup>, M. Luciano<sup>1</sup>, M. Torella<sup>2</sup> and A. Fiorillo<sup>1</sup>

<sup>1</sup>Psychiatry, University of Campania "Luigi Vanvitelli", napoli, Italy and <sup>2</sup>Gynecology And Obstetrics, University of Campania "Luigi Vanvitelli", napoli, Italy

\*Corresponding author.

doi: 10.1192/j.eurpsy.2021.312

**Introduction:** Perinatal depression is a severe and disabling condition, which affects negatively both mothers' and children's mental health and well-being. About 12.8% of pregnant women report depressive symptoms in the perinatal period.

**Objectives:** The aims of the present study are to: 1) identify factors (socio-demographic and clinical) associated with an increased risk of developing PD; 2) promote a screening program on PD.

**Methods:** All pregnant women were assessed at each trimester of pregnancy, three days after the childbirth and after 1, 3, 6 and 12 months, with the Edinburgh Postpartum Depression Scale (EPDS). Women scoring  $\geq 10$  on the EPDS were invited to receive a full psychiatric evaluation to confirm the diagnosis.

**Results:** 420 women were recruited. 52.9%, 27.6% and 31.6% of participants presented an EPDS  $\geq 10$  score at The I, II and III trimester of pregnancy, respectively. The percentage of patients with and EPS score  $\geq 19$  is 16.6%, 6.8%, 6.8%, 11.3% and 7.8% in 3 days following the childbirth and after 3, 6, 9 and 12 months, respectively. Higher EPDS scores are predicted by the presence of anxiety symptoms before pregnancy and of depressive and anxiety symptoms in previous pregnancies ( $p<0.05$ ). Women with family conflicts and with anxiety symptoms in the partner are more likely to report higher EPDS scores ( $p<0.001$ ).

**Conclusions:** Our results confirm that perinatal depression is a highly prevalent condition. An early identification of depressive symptoms during this period is crucial in order to reduce the long-term negative impact on the mothers, the newborn and other family members.

**Disclosure:** No significant relationships.

**Keywords:** Perinatal depression; depressive symptoms; risk-factors; longitudinal study

## O109

### A specific "at risk" profile related to recent stressful life events in euthymic major depressive disorder

G. Serafini<sup>1\*</sup>, X. Gonda<sup>2</sup>, A. Aguglia<sup>1</sup>, A. Amerio<sup>1</sup>, G. Canepa<sup>1</sup>, P. Geoffroy<sup>3</sup>, M. Pompili<sup>4</sup> and M. Amore<sup>5</sup>

<sup>1</sup>Department Of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal And Child Health (dinogmi), University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy;

<sup>2</sup>Department Of Psychiatry And Psychotherapy, Semmelweis University, Budapest, Hungary; <sup>3</sup>Psychiatry And Addiction Medicine Department, Hôpital Bichat Claude-Bernard, Assistance Publique - Hôpitaux de Paris, Paris, France; <sup>4</sup>Departement Of Neurosciences,